TOPSTAR研究PPT课件.pptVIP

TOPSTAR Design Single center, double-blind, randomized, prospective study of ELECTIVE PCI patients Assessed the additive benefit of administering a GP IIb-IIIa inhibitor to the treatment regimen of aspirin, unfractionated heparin, and clopidogrel. This additive benefit was assessed in terms of: Cardiac troponin (TnT) release post-elective PCI; and The incidence of death, MI, and target vessel revascularization (TVR) at 9 months. TOPSTAR Background Elevated cardiac troponin pre-PCI is associated with a higher risk of mortality. TOPSTAR assessed the association of post PCI troponin with the a